Artificial Intelligence in Colorectal Cancer: From Patient Screening over Tailoring Treatment Decisions to Identification of Novel Biomarkers
Digestion · 12.06.2024 · 105 (5) · 331-344
DOI: 10.1159/000539678 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Digestion, online erschienen am 12.06.2024. Verfasst von Nic Gabriel Reitsam und 4 weiteren Autor:innen. Beteiligte Einrichtung: Pathology, Faculty of Medicine, University of Augsburg, Augsburg, Germany, nic.reitsam@uka-science.de. Hauptthemen laut MEDLINE: Colorectal Neoplasms, Artificial Intelligence, Biomarkers, Tumor, Early Detection of Cancer. Die Arbeit wurde bisher 27-mal zitiert (Crossref) und nennt 132 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background: Artificial intelligence (AI) is increasingly entering and transforming not only medical research but also clinical practice. In the last 10 years, new AI methods have enabled computers to perform visual tasks, reaching high performance and thereby potentially supporting and even outperforming human experts. This is in particular relevant for colorectal cancer (CRC), which is the 3rd most common cancer type in general, as along the CRC patient journey many complex visual tasks need to be performed: from endoscopy over imaging to histopathology; the screening, diagnosis, and treatment of CRC involve visual image analysis tasks. Summary: In all these clinical areas, AI models have shown promising results by supporting physicians, improving accuracy, and providing new biological insights and biomarkers. By predicting prognostic and predictive biomarkers from routine images/slides, AI models could lead to an improved patient stratification for precision oncology approaches in the near future. Moreover, it is conceivable that AI models, in particular together with innovative techniques such as single-cell or spatial profiling, could help identify novel clinically as well as biologically meaningful biomarkers that could pave the way to new therapeutic approaches. Key Messages: Here, we give a comprehensive overview of AI in colorectal cancer, describing and discussing these developments as well as the next steps which need to be taken to incorporate AI methods more broadly into the clinical care of CRC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Pathology, Faculty of Medicine, University of Augsburg, Augsburg, Germany, nic.reitsam@uka-science.de.
- Bavarian Cancer Research Center (BZKF), Augsburg, Germany, nic.reitsam@uka-science.de.
- Nuclear Medicine, Faculty of Medicine, University of Augsburg, Augsburg, Germany.
- Division of Gastroenterology, Medical Department II, University of Leipzig Medical Center, Leipzig, Germany.
- Pathology, Faculty of Medicine, University of Augsburg, Augsburg, Germany.
- Bavarian Cancer Research Center (BZKF), Augsburg, Germany.
Zitieren
APA
Reitsam, N. G., Enke, J. S., Vu Trung, K., Märkl, B., & Kather, J. N. (2024). Artificial Intelligence in Colorectal Cancer: From Patient Screening over Tailoring Treatment Decisions to Identification of Novel Biomarkers. Digestion, 105(5), 331-344. https://doi.org/10.1159/000539678
Vancouver
Reitsam NG, Enke JS, Vu Trung K, Märkl B, Kather JN. Artificial Intelligence in Colorectal Cancer: From Patient Screening over Tailoring Treatment Decisions to Identification of Novel Biomarkers. Digestion. 2024;105(5):331-344. doi:10.1159/000539678
BibTeX
@article{Reitsam2024,
author = {Reitsam, Nic Gabriel and Enke, Johanna Sophie and Vu Trung, Kien and Märkl, Bruno and Kather, Jakob Nikolas},
title = {Artificial Intelligence in Colorectal Cancer: From Patient Screening over Tailoring Treatment Decisions to Identification of Novel Biomarkers},
journal = {Digestion},
year = {2024},
volume = {105},
number = {5},
pages = {331--344},
doi = {10.1159/000539678}
}
EUVIMED